ClinicalTrials.gg
RecruitingNCT06261840Updated May 6, 2026

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

A Phase 4 interventional study of Metronidazole 500 mg and Secnidazole 2000 MG in Trichomonas Vaginitis and Bacterial Vaginitis, sponsored by Tulane University. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Tulane University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

Read the detailed description

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men. The goal is to refine T. vaginalis treatment for women and men by examining the effectiveness (Aim 1) and cost-effectiveness (Aim 2) of multi-dose oral MTZ versus single-dose oral SEC. The investigators have several secondary analyses for Aim 1 including to examine if bacterial vaginosis (BV) interferes with T. vaginalis treatment, to explore preferences for follow-up visits, and to examine the natural history of T. vaginalis infection in both sexes.

If single-dose oral SEC is found to be superior to multi-dose oral MTZ, this could potentially result in an estimated 280,000 people in the U.S./year receiving better care, having fewer adverse sexual and reproductive health outcomes, and having a reduced risk for HIV acquisition. It will also provide patients with a single-dose oral treatment option that will be particularly attractive for subjects with concomitant T. vaginalis and BV.

02

Conditions studied

  • Trichomonas Vaginitis
  • Bacterial Vaginitis
03

In context

Trichomonas Vaginitis

22 studies on the registry are indexed under Trichomonas Vaginitis; 3 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 351 across 15 interventional studies indexed under Trichomonas Vaginitis.

Browse Trichomonas Vaginitis studies →

Lead sponsor

Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men aged 18 years or older of any race/ethnicity will be included in the study.
  • Participants must have either a positive T. vaginalis rapid antigen test (OSOM), or wet mount microscopy with motile trichomonads, or nucleic acid amplification test (NAAT) urinalysis or Pap smear positive for TV within two weeks of available results (and have not yet been treated) that is confirmed by repeat T. vaginalis NAAT testing at study enrollment,
  • Willing and able to provide and understand to comply with the study protocol,
  • Have a method of contact (either phone, email or social media),
  • Be willing to be randomized.

Exclusion criteria

Exclusion Criteria:

  • Pregnant/lactating or seeking to be pregnant
  • Have been treated for with a 5-nitroimidazole (i.e. Metronidazole (MTZ), tinidazole (TDZ), or secnidazole [SEC]) in the last 28 days
  • Used intravaginal boric acid or any other intravaginal treatment for T. vaginalis in the last 14 days
  • Have a history of a type 1 reaction to 5-nitroimidazole medications
  • Are taking phenytoin (Dilantin) and/or warfarin (Coumadin) due to drug-drug interactions with oral MTZ
  • Use of medications which may alter the metabolism of MTZ including Lithium and barbiturates (amobarbital, butalbital, methohexital, phenobarbital, pentobarbital, primidone, secobarbital)
  • Have been previously enrolled in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Oral Multi-Dose Metronidazole

    Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men

    Drug: Metronidazole 500 mg

  • Experimental
    Single-Dose Secnidazole

    Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men

    Drug: Secnidazole 2000 MG

Interventions

  • DrugMetronidazoleStudies of MetronidazoleMetronidazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men

    Also known as: FLAGYL

  • DrugSecnidazoleStudies of SecnidazoleSecnidazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men

    Also known as: SOLOSEC

06

What researchers measure

Primary outcomes

  1. Treatment, as Measured by the Number of Participants that are Cured of Trichomonas Vaginalis at one month test of cure.

    A repeat T. vaginalis NAAT test will be completed at the test of cure (TOC) visit

    Time frame: A TOC visit will be scheduled 4 weeks (+- 1 week) after post completion of treatment

Secondary outcomes

  1. To examine if BV co-infection interferes with T. vaginalis treatment

    Of those who test positive for BV via BV OSOM at baseline, those who re-test positive via BV OSOM at one-month test-of-cure will be compared by treatment arm.

    Time frame: From enrollment to completion of one-month test of cure for those who test BV positive at baseline.

  2. To examine if oral single-dose secnidazole is superior to oral multi-dose metronidazole for the treatment of BV.

    We will conduct a secondary analysis to compare the effectiveness of oral single-dose secnidazole versus oral multi-dose metronidazole among women enrolled in the trial with a diagnosis of BV at baseline. Those who test positive for BV via BV OSOM at baseline will be re-tested and BV positivity at one-month will be compared by treatment arm.

    Time frame: From baseline visit to one-month test of cure visit

  3. A comparison of participant preferences for the test-of-cure (TOC) visit (in clinic versus telemedicine) as captured on baseline survey.

    Participants will be asked their preference for an in person one-month test of cure visit that is in person versus telehealth.

    Time frame: From baseline visit to one-month test of cure visit

  4. A comparison of TV NAAT confirmatory test results to determine the percentage who spontaneously clear the infection without medication.

    Women and men who previously tested positive for T. vaginalis by nucleic acid amplification test (NAAT) will be retested by NAAT at study entry. The rate of early spontaneous resolution will be calculated.

    Time frame: at baseline, we document their prior test result (per medical records, survey or onsite testing).

07

Study locations

3 of 4 sites recruiting
  • University of Alabama at Birmingham [UAB] Gynecology Clinics
    Birmingham, Alabama 25233, United States
    Recruiting
    • Stephanie Clevenger · Contactslangan@uabmc.edu · 205-934-0877
    • Janeen Arbuckle · Sub investigator
  • UAB Sexual Health Research Clinic [SHRC]
    Birmingham, Alabama 35205, United States
    Recruiting
    • Saralyn Richter · Contactsrichter@uabmc.edu · 205-934-8166
    • Christina Muzny · Principal investigator
  • Segal Trials Healthcare Clinical Data, Inc. 1065 NE 125th St. Suite 417 North Miami, FL 33161
    North Miami, Florida 33161, United States
    Not yet recruiting
  • LSU-CrescentCare Sexual Health Center
    New Orleans, Louisiana 70119, United States
    Recruiting
    • Catherine Cammarata · ContactCCamma@lsuhsc.edu · 504-568-4132
    • Rebecca Lillis · Sub investigator
08

References and documents

Publications

  • Muzny CA, Lillis RA, Chavoustie SE, Arbuckle JL, Van Gerwen OT, Sagoe M, Kandregula AR, Srivastav S, Kissinger PJ. Refining Trichomonas vaginalis treatment in women and men: protocol for an open-label randomised comparison of multi-dose oral metronidazole versus single-dose oral secnidazole. BMJ Open. 2026 Apr 24;16(4):e116003. doi: 10.1136/bmjopen-2025-116003. PubMed 42031495 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for May 2029, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Feb 15, 2024
StartActual
May 6, 2025
Primary completionEst.
May 1, 2029
CompletionEst.
Jul 31, 2029
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06261840
Lead sponsor
Tulane University
Collaborators
University of Alabama at Birmingham, Louisiana State University Health Sciences Center in New Orleans, Healthcare Clinical Data
Responsible party
Patricia Kissinger (Principal Investigator, Tulane University) — Principal investigator
First posted
Feb 15, 2024
Start date
May 6, 2025
Primary completion
May 1, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
May 6, 2026

Study contacts

Patricia Kissinger, PhD
Contact
kissing@tulune.edu
504-988-7320
Christina Muzny, MD
Contact
cmuzny@uabmc.edu
205-975-3298
Patricia Kissinger, PhD
principal investigator · Tulane University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metronidazole · Secnidazole

Start the discussion